Margaret A Shipp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4286806/publications.pdf

Version: 2024-02-01

116 papers	25,946 citations	23879 60 h-index	33145 104 g-index
118 all docs	118 docs citations	118 times ranked	27512 citing authors

#	Article	IF	Citations
1	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	0.6	512
2	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 1353-1364.	0.6	31
3	MYD88 L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8. Blood, 2021, 138, 1324-1324.	0.6	0
4	Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 713-713.	0.6	0
5	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine, 2020, 26, 1468-1479.	15.2	87
6	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica, 2020, 105, 1361-1368.	1.7	23
7	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Advances, 2020, 4, 122-126.	2.5	46
8	Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. Blood, 2020, 136, 42-43.	0.6	0
9	SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. Blood, 2020, 136, 23-24.	0.6	9
10	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 2019, 134, 1144-1153.	0.6	255
11	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 3291-3299.	0.8	195
12	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Journal of Clinical Oncology, 2019, 37, 1997-2007.	0.8	170
13	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019, 134, 22-29.	0.6	129
14	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. Journal of Clinical Oncology, 2019, 37, 481-489.	0.8	265
15	The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative. Blood, 2019, 134, 2059-2069.	0.6	66
16	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood, 2019, 134, 2369-2382.	0.6	72
17	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Advances, 2019, 3, 4065-4080.	2.5	99
18	Targeted inhibition of PI3KÎ±/Î´ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood, 2019, 133, 70-80.	0.6	75

#	Article	IF	Citations
19	Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. Blood, 2019, 134, 240-240.	0.6	20
20	Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade. Blood, 2019, 134, 1493-1493.	0.6	0
21	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 2018, 24, 679-690.	15.2	1,224
22	Reply to Z. Wu et al. Journal of Clinical Oncology, 2018, 36, 2657-2657.	0.8	0
23	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology, 2018, 36, 1428-1439.	0.8	551
24	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 942-950.	0.8	273
25	Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cellâ€“rich and exhausted T-effector microenvironment. Blood, 2018, 132, 825-836.	0.6	121
26	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. Blood, 2018, 132, 228-228.	0.6	14
27	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood, 2018, 132, 1650-1650.	0.6	2
28	Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. Blood, 2018, 132, 2932-2932.	0.6	10
29	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. Blood, 2018, 132, 706-706.	0.6	3
30	Novel Epigenetic Vulnerabilities for Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 2600-2600.	0.6	1
31	Comprehensive Genomic Analysis of Primary Mediastinal B-Cell Lymphoma. Blood, 2018, 132, 1564-1564.	0.6	4
32	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. Blood, 2018, 132, 1579-1579.	0.6	2
33	Targeted Inhibition of PI3K Î±/Î´ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL. Blood, 2018, 132, 39-39.	0.6	0
34	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood, 2017, 130, 267-270.	0.6	255
35	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood, 2017, 130, 2420-2430.	0.6	262
36	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood, 2017, 130, 2265-2270.	0.6	53

#	Article	IF	Citations
37	Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death and Differentiation, 2017, 24, 251-262.	5.0	65
38	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Hematology American Society of Hematology Education Program, 2017, 2017, 310-316.	0.9	18
39	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 2125-2132.	0.8	830
40	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology, 2016, 34, 2690-2697.	0.8	634
41	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
42	NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5999-6004.	3.3	198
43	Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood, 2016, 127, 869-881.	0.6	429
44	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood, 2016, 127, 2203-2213.	0.6	68
45	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncology, The, 2016, 17, 1283-1294.	5.1	818
46	Classical Hodgkin Lymphoma with Reduced Î²2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 2016, 4, 910-916.	1.6	146
47	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology, 2016, 34, 2698-2704.	0.8	868
48	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. Journal of Clinical Oncology, 2016, 34, 3733-3739.	0.8	586
49	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncology, 2016, 2, 518.	3.4	121
50	In Silico and Functional Characterization of TBL1XR1 as a Tumor Suppressor in Large B-Cell Lymphomas. Blood, 2016, 128, 612-612.	0.6	4
51	A roadmap for discovery and translation in lymphoma. Blood, 2015, 125, 2175-2177.	0.6	18
52	The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma InÂVivo. Cell, 2015, 161, 319-332.	13.5	293
53	Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. Journal of Molecular Diagnostics, 2015, 17, 19-30.	1.2	25
54	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 372, 311-319.	13.9	3,099

#	Article	IF	Citations
55	Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain. American Journal of Surgical Pathology, 2014, 38, 1715-1723.	2.1	138
56	Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors. Cell, 2014, 156, 744-758.	13.5	423
57	Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo. Clinical Cancer Research, 2014, 20, 2674-2683.	3.2	114
58	PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research, 2013, 19, 3462-3473.	3.2	721
59	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. Cancer Cell, 2013, 24, 777-790.	7.7	635
60	SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas. Cancer Cell, 2013, 23, 826-838.	7.7	152
61	BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8. Molecular and Cellular Biology, 2013, 33, 845-857.	1.1	96
62	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 3021-3021.	0.6	1
63	Preclinical Analyses Of The Chemical JAK2 Inhibitor, SAR302503, In Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. Blood, 2013, 122, 4230-4230.	0.6	1
64	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 631-631.	0.6	1
65	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3879-3884.	3.3	853
66	Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy. Clinical Cancer Research, 2012, 18, 1611-1618.	3.2	582
67	Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 22, 547-560.	7.7	422
68	Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 22, 359-372.	7.7	179
69	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1534-1534.	0.6	0
70	Galectin-1 Serum Levels Reflect Tumor Burden and Adverse Clinical Features in Hodgkin Lymphoma. Blood, 2012, 120, 51-51.	0.6	0
71	Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood, 2011, 117, 4315-4322.	0.6	75
72	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010, 116, 3268-3277.	0.6	1,122

#	Article	IF	Citations
73	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica, 2010, 95, 2056-2062.	1.7	28
74	No Evidence for the JAK2 (V617F) or JAK2 Exon 12 Mutations in Primary Mediastinal Large B-cell Lymphoma. Diagnostic Molecular Pathology, 2009, 18, 144-149.	2.1	10
75	The heat shock protein 90 inhibitor IPIâ€504 induces apoptosis of AKTâ€dependent diffuse large Bâ€cell lymphomas. British Journal of Haematology, 2009, 144, 358-366.	1.2	30
76	BBAP Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response. Molecular Cell, 2009, 36, 110-120.	4.5	133
77	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood, 2009, 114, 5315-5321.	0.6	53
78	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood, 2008, 111, 2230-2237.	0.6	289
79	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3207-3212.	3.3	130
80	The AP1-dependent secretion of galectin-1 by Reedâ€“Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13134-13139.	3.3	299
81	Molecular Signatures Define New Rational Treatment Targets in Large B-Cell Lymphomas. Hematology American Society of Hematology Education Program, 2007, 2007, 265-269.	0.9	12
82	Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2007, 25, 1741-1746.	0.8	235
83	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 2007, 110, 2067-2074.	0.6	117
84	Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma. American Journal of Surgical Pathology, 2007, 31, 106-112.	2.1	77
85	BH3 Profiling Identifies Three Distinct Classes of Apoptotic Blocks to Predict Response to ABT-737 and Conventional Chemotherapeutic Agents. Cancer Cell, 2007, 12, 171-185.	7.7	457
86	Detecting Apoptotic Blocks and Sensitvity to ABT-737 and Conventional Chemotherapy Via BH3 Profiling.. Blood, 2007, 110, 4523-4523.	0.6	0
87	BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate. Molecular and Cellular Biology, 2006, 26, 5348-5359.	1.1	107
88	Tonic B-Cell Receptor Signaling Promotes the Survival of Diffuse Large B-Cell Lymphomas: Identification of SYK as a Rational Treatment Target.. Blood, 2006, 108, 226-226.	0.6	6
89	Hodgkinâ€™s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.. Blood, 2006, 108, 469-469.	0.6	1
90	Protein Tyrosine Phosphatase Receptor-Type O Truncated (PTPROT) Regulates SYK Phosphorylation, Proximal B-Cell Receptor Signaling and Cellular Proliferation.. Blood, 2006, 108, 933-933.	0.6	0

#	Article	IF	Citations
91	Heat Shock Protein 90 (HSP90) Is a Rational Therapeutic Target in Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 829-829.	0.6	0
92	The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKTâ€“dependent apoptosis in diffuse large B-cell lymphoma. Blood, 2005, 105, 308-316.	0.6	141
93	NFÂB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood, 2005, 106, 1392-1399.	0.6	229
94	Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood, 2005, 106, 1164-1174.	0.6	194
95	B-aggressive Lymphoma Family Proteins Have Unique Domains That Modulate Transcription and Exhibit Poly(ADP-ribose) Polymerase Activity. Journal of Biological Chemistry, 2005, 280, 33756-33765.	1.6	135
96	Case 12-2005. New England Journal of Medicine, 2005, 352, 1697-1704.	13.9	6
97	Tumor Cell-mediated Induction of the Stromal Factor Stromelysin-3 Requires Heterotypic Cell Contact-dependent Activation of Specific Protein Kinase C Isoforms. Journal of Biological Chemistry, 2005, 280, 1272-1283.	1.6	8
98	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 2005, 105, 1851-1861.	0.6	778
99	B-Aggressive Lymphoma (BAL) Family Proteins Have Unique Domains Which Modulate Transcription and Exhibit PARP Activity.. Blood, 2005, 106, 2400-2400.	0.6	1
100	Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies.. Blood, 2005, 106, 3346-3346.	0.6	1
101	Inactivation of the PRDM1/BLIMP1 Gene in Non-GC-Type Diffuse Large B-Cell Lymphoma.. Blood, 2005, 106, 2614-2614.	0.6	0
102	Signatures of Response to the Proteasome Inhibitor Bortezomib in Diffuse Large B-Cell Lymphoma.. Blood, 2005, 106, 608-608.	0.6	0
103	FAS Death Domain Deletions and Increased c-FLIPlong Expression Occur in Different Subtypes of Diffuse Large B-Cell Lymphoma.. Blood, 2005, 106, 416-416.	0.6	0
104	NFÎºB Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NFÎºB Target Genes.. Blood, 2004, 104, 243-243.	0.6	11
105	B-Aggressive Lymphoma Gene (BAL) Is a Risk-Related, Î³IFN-Inducible Gene That Is Expressed in Primary Diffuse Large B-Cell Lymphomas with a Brisk Host Inflammatory Response.. Blood, 2004, 104, 2035-2035.	0.6	5
106	Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase. International Journal of Cancer, 2003, 106, 355-363.	2.3	22
107	The BAL-binding Protein BBAP and Related Deltex Family Members Exhibit Ubiquitin-Protein Isopeptide Ligase Activity. Journal of Biological Chemistry, 2003, 278, 21930-21937.	1.6	120
108	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood, 2003, 102, 3871-3879.	0.6	793

#	Article	IF	Citations
109	Molecular Diagnostics. Hematology American Society of Hematology Education Program, 2003, 2003, 279-293.	0.9	19
110	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 2002, 8, 68-74.	15.2	2,217
111	Stromelysin-3 suppresses tumor cell apoptosis in a murine model. Journal of Cellular Biochemistry, 2001, 82, 549-555.	1.2	56
112	BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood, 2000, 96, 4328-4334.	0.6	110
113	Stromelysin-3 Is Induced in Tumor/Stroma Cocultures and Inactivated via a Tumor-specific and Basic Fibroblast Growth Factor-dependent Mechanism. Journal of Biological Chemistry, 1998, 273, 618-626.	1.6	52
114	A Directly Spliced Exon 10â€“Containing CD44 Variant Promotes the Metastasis and Homotypic Aggregation of Aggressive Non-Hodgkin's Lymphoma. Blood, 1998, 91, 4282-4291.	0.6	26
115	Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Cancer, 1991, 68, 699-705.	2.0	23
116	Downregulation of enkephalin-mediated inflammatory responses by CDl0/neutral endopeptidase 24.11. Nature, 1990, 347, 394-396.	13.7	165